Biosimilar medicines began to be made available in Portugal in 2008, with their approval and gradual introduction into the Unified Health System.
Health (SNS in Portuguese). Its use has been increasing, representing an important opportunity to reduce costs with biological therapies, which are
often high. This allows for increased patient access to therapy, while contributing to the sustainability of the healthcare system.
health. Additionally, the use of biosimilars can free up financial resources that can be allocated to new drugs or other areas of research.
need in the SNS.
To maximize the benefits of biosimilars in the Portuguese context, it is essential to continue promoting education on their use, reinforcing policies
encourage its development and ensure clear implementation strategies in the SNS Local Health Units. Such measures can increase the
use of these medicines, improving resource management and expanding access to quality health care.
The growing relevance of biosimilar medicines in the public health scenario has led many countries to adopt specific strategies for their
regulation, implementation and monitoring. In Portugal, health authorities have played a central role in promoting these medicines,
with the aim of increasing accessibility and reducing costs. Through regulation and implementation of public policies, the country has encouraged the use
of these drugs as more economical therapeutic alternatives.
The evolution of market share of biosimilar is:
Source: INFARMED
The text above is owned by the site above referred.
Here is only a small part of the article, for more please follow the link
Also see:
Manostaxx – Industrial Management Consulting
